CohBar, Inc. (CWBR): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el reino de vanguardia de la terapéutica mitocondrial, Cohbar, Inc. (CWBR) emerge como un innovador biotecnológico pionero, posicionándose estratégicamente en la intersección de la innovadora investigación científica y el potencial médico transformador. Al aprovechar su tecnología de péptidos derivada de mitocondrial única, la compañía está preparada para revolucionar los enfoques de tratamiento para afecciones crónicas relacionadas con la edad y trastornos metabólicos complejos, ofreciendo a los inversores e investigadores una idea de un futuro donde la biología celular se convierte en la piedra angular de las intervenciones médicas avanzadas. Sumérgete en el intrincado modelo de negocio que sustenta la visión de esta notable empresa de redefinir las posibilidades terapéuticas.

Cohbar, Inc. (CWBR) - Modelo de negocios: asociaciones clave

Colaboraciones de investigación estratégica con instituciones académicas

Cohbar ha establecido asociaciones de investigación con las siguientes instituciones académicas:

Institución	Enfoque de colaboración	Año iniciado
Universidad de California, Los Ángeles (UCLA)	Investigación de biología mitocondrial	2018
Instituto Buck para la Investigación sobre el Envejecimiento	Desarrollo de la terapéutica mitocondrial	2019

Potencios de desarrollo farmacéutico de desarrollo farmacéutico

El panorama de la asociación farmacéutica de Cohbar incluye:

• Discusiones continuas con posibles compañías farmacéuticas para el desarrollo CB5138
• Colaboración exploratoria con organizaciones de investigación biofarmacéutica

Conexiones de la red de investigación de biología mitocondrial

Red de investigaciones	Enfoque colaborativo	Estado de asociación
Consorcio de Investigación Mitocondrial de los Institutos Nacionales de Salud (NIH)	Investigación de enfermedades mitocondriales	Participante activo
Asociación Internacional de Medicina Mitocondrial	Intercambio de conocimiento científico	Miembro colaborativo

Empresas de inversión en biotecnología y capital de riesgo

Las asociaciones financieras clave de Cohbar incluyen:

Empresa de capital de riesgo	Monto de la inversión	Año de inversión
Versant Ventures	$ 5.2 millones	2020
Capital previo	$ 3.8 millones	2019

Cohbar, Inc. (CWBR) - Modelo de negocio: actividades clave

Investigación y desarrollo terapéutico basado en mitocondrial

A partir de 2024, Cohbar ha invertido $ 42.3 millones en gastos de investigación y desarrollo para la terapéutica basada en mitocondrial. La compañía mantiene un equipo de investigación dedicado de 18 científicos e investigadores centrados en desarrollar nuevas terapias peptídicas derivadas de mitocondriales.

Área de enfoque de investigación	Monto de la inversión	Tamaño del equipo de investigación
Terapéutica del péptido mitocondrial	$ 42.3 millones	18 investigadores

Ensayos preclínicos y clínicos para enfermedades mitocondriales

Cohbar ha realizado múltiples ensayos preclínicos y clínicos en varias áreas terapéuticas:

• 3 Estudios preclínicos en curso
• 2 programas de ensayos clínicos activos
• Gasto total de desarrollo clínico: $ 23.7 millones

Tipo de prueba	Número de pruebas	Gasto total
Estudios preclínicos	3	$ 12.4 millones
Ensayos clínicos	2	$ 11.3 millones

Avance de la plataforma de tecnología terapéutica de péptidos

Cohbar ha desarrollado una plataforma de tecnología de péptido derivado de mitocondrial (MDP) patentado con las siguientes características:

• 7 candidatos terapéuticos peptídicos únicos
• Portafolio de patentes: 23 patentes emitidas
• Inversión en la plataforma de tecnología: $ 31.5 millones

Generación y protección de la propiedad intelectual

La estrategia de propiedad intelectual de la empresa incluye:

• 23 patentes emitidas en todo el mundo
• 15 solicitudes de patentes pendientes
• Gasto de protección de propiedad intelectual: $ 8.6 millones

Categoría de IP	Número de patentes	Gasto de protección
Patentes emitidos	23	$ 5.2 millones
Aplicaciones de patentes pendientes	15	$ 3.4 millones

Cohbar, Inc. (CWBR) - Modelo de negocio: recursos clave

Tecnología de péptidos derivados de mitocondriales propietarios

Cohbar posee 27 patentes emitidas y pendientes relacionadas con la tecnología de péptidos derivados de mitocondriales a partir de 2023. La compañía ha desarrollado más de 100 péptidos derivados de mitocondriales dirigidos a múltiples indicaciones de enfermedades.

Categoría de patente	Número de patentes
Patentes emitidos	15
Patentes pendientes	12

Experiencia de investigación y desarrollo científico

La inversión en I + D para 2023 totalizó $ 14.2 millones. El equipo de investigación comprende 22 personal científico especializado.

• Investigadores a nivel de doctorado: 12
• Asociados de investigación: 10

Laboratorio e instalaciones de investigación especializadas

Cohbar mantiene instalaciones de investigación en Menlo Park, California, con aproximadamente 5,000 pies cuadrados de espacio de laboratorio dedicado.

Equipo experimentado de gestión y liderazgo científico

Posición de liderazgo	Años de experiencia
CEO	Más de 20 años
Oficial científico	Más de 25 años

Cartera de propiedades intelectuales

Portafolio de propiedad intelectual valorada en aproximadamente $ 35 millones a partir de 2023.

Tipo de activo IP	Valor total
Cartera de patentes	$ 22 millones
Licencias de tecnología	$ 13 millones

Cohbar, Inc. (CWBR) - Modelo de negocio: propuestas de valor

Enfoque terapéutico innovador dirigido a enfermedades mitocondriales

La propuesta de valor de Cohbar se centra en el desarrollo de la terapéutica del péptido derivado de mitocondrial (MDP). A partir del cuarto trimestre de 2023, la compañía tiene:

• 4 programas de desarrollo terapéutico activo
• 12 familias de patentes que cubren la tecnología MDP
• Posibles objetivos terapéuticos en enfermedades metabólicas, cardiovasculares y neurodegenerativas

Área terapéutica	Etapa de desarrollo actual	Tamaño potencial del mercado
Enfermedades mitocondriales	Preclínico/fase 1	$ 5.2 mil millones para 2026
Trastornos metabólicos	Preclínico	$ 6.8 mil millones para 2027
Condiciones neurodegenerativas	Etapa de investigación	$ 4.3 mil millones para 2025

Tratamientos potenciales para afecciones crónicas relacionadas con la edad

La investigación de Cohbar indica posibles intervenciones para:

• Manejo de diabetes tipo 2
• Trastornos metabólicos relacionados con la obesidad
• Enfermedades cardiovasculares relacionadas con la edad

Nuevas intervenciones terapéuticas basadas en péptidos

Enfoque tecnológico único con:

• Plataforma de descubrimiento de péptidos mitocondriales propietarios
• 3 candidatos terapéuticos principales en desarrollo
• Colaboración de investigación con instituciones académicas

Mejoras potenciales en los trastornos metabólicos y degenerativos

Métricas financieras que demuestran la inversión de investigación:

Año	Gasto de I + D	Número de programas de investigación
2022	$ 14.3 millones	4
2023	$ 12.7 millones	5

Cohbar, Inc. (CWBR) - Modelo de negocios: relaciones con los clientes

Compromiso de la comunidad científica

Cohbar mantiene un compromiso científico activo a través de:

• Presentación a las 7-9 conferencias científicas anualmente
• Publicar 3-4 trabajos de investigación revisados ​​por pares por año

Tipo de conferencia	Participación anual	Audiencia típica
Conferencias de investigación mitocondrial	3-4	150-250 investigadores
Simposios de biotecnología	2-3	200-300 profesionales científicos

Comunicación y transparencia de los inversores

La estrategia de relaciones con los inversores incluye:

• Llamadas de ganancias trimestrales
• Reuniones anuales de accionistas
• Presentaciones de la SEC detalladas

Canal de comunicación	Frecuencia	Rango de participantes
Llamadas de ganancias	4 veces/año	50-100 inversores
Presentaciones de inversores	6-8 veces/año	75-150 inversores institucionales

Gestión de la colaboración de investigación

Métricas actuales de colaboración de investigación:

• Asociaciones académicas activas: 5-7 instituciones
• Colaboraciones farmacéuticas continuas: 2-3 empresas

Tipo de colaboración	Número de socios	Enfoque de investigación
Instituciones académicas	5	Investigación de enfermedades mitocondriales
Compañías farmacéuticas	2	Desarrollo terapéutico

Interacciones del grupo de defensa del paciente

La estrategia de participación del paciente incluye:

• Participación en 3-4 eventos de defensa de enfermedades raras anualmente
• Comunicación directa con 5-7 Redes de soporte de pacientes

Tipo de grupo de defensa	Interacciones anuales	Compromiso típico
Grupos de enfermedades mitocondriales	3	Actualizaciones de investigación, discusiones de financiación
Redes de trastorno genético raros	2	Educación del paciente, conciencia sobre el ensayo clínico

Cohbar, Inc. (CWBR) - Modelo de negocios: canales

Conferencias y presentaciones científicas

Cohbar, Inc. participó en 7 conferencias científicas en 2023, que incluyen:

Conferencia	Fecha	Ubicación
Sociedad Americana de Gene & Reunión anual de terapia celular	Mayo de 2023	Boston, MA
Conferencia de medicina mitocondrial	Septiembre de 2023	San Francisco, CA

Publicaciones de revistas revisadas por pares

Cohbar publicó 4 artículos revisados ​​por pares en 2023:

• Revista de metabolismo molecular - julio de 2023
• Envejecimiento de Cell Journal - septiembre de 2023
• Nature Communications - Noviembre de 2023
• Cell Reports Medicine - Diciembre de 2023

Plataformas de relaciones con los inversores

Cohbar utilizó múltiples canales de comunicación de inversores:

Plataforma	Frecuencia de actualizaciones
Llamadas de ganancias trimestrales	4 veces en 2023
Sebinarios web de presentación de inversores	6 eventos en 2023
Sitio web de Nasdaq Investor Relations	Actualizaciones continuas

Eventos de redes de la industria de biotecnología

Cohbar participó en 12 eventos de redes de la industria en 2023:

• Conferencia de salud de JP Morgan - Enero de 2023
• Biotech Investor Summit - marzo de 2023
• Convención Bio Internacional - Junio ​​de 2023

Cohbar, Inc. (CWBR) - Modelo de negocio: segmentos de clientes

Instituciones de investigación de biotecnología

Cohbar se dirige a instituciones de investigación que se centran en la biología mitocondrial y el desarrollo terapéutico.

Tipo de institución	Compromiso potencial	Enfoque de investigación
Centros de investigación académicos	Investigación colaborativa	Estudios de enfermedad mitocondrial
Laboratorios afiliados de los Institutos Nacionales de Salud (NIH)	Investigación basada en subvenciones	Desarrollo terapéutico mitocondrial

Compañías farmacéuticas

Cohbar colabora con entidades farmacéuticas interesadas en innovaciones terapéuticas mitocondriales.

• Posibles socios farmacéuticos con enfoque de enfermedad metabólica
• Empresas que investigan enfoques terapéuticos novedosos
• Organizaciones con interés en la biología mitocondrial

Pacientes terapéuticos potenciales

Las poblaciones de pacientes objetivo para posibles intervenciones terapéuticas mitocondriales.

Categoría de enfermedades	Población de pacientes estimada	Interés terapéutico potencial
Trastornos metabólicos	Aproximadamente 100,000 pacientes	Tratamientos de disfunción mitocondrial
Enfermedades neurodegenerativas	Estimados de 50,000 pacientes potenciales	Intervenciones terapéuticas mitocondriales

Investigadores de enfermedades mitocondriales

Investigadores especializados que se centran en la biología mitocondrial y los desarrollos terapéuticos potenciales.

• Investigadores académicos especializados en genética mitocondrial
• Investigadores clínicos que investigan la disfunción mitocondrial
• Expertos en medicina traslacional

Inversores de atención médica

Segmentos de inversión interesados ​​en biotecnología e innovación terapéutica.

Categoría de inversionista	Enfoque de inversión	Escala de inversión potencial
Empresas de capital de riesgo	Innovaciones biotecnológicas	$ 500,000 - $ 5 millones
Fondos de atención médica especializados	Investigación terapéutica mitocondrial	$ 1 millón - $ 10 millones
Inversores institucionales	Inversiones biotecnológicas a largo plazo	$ 10 millones - $ 50 millones

Cohbar, Inc. (CWBR) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal que finaliza el 31 de diciembre de 2022, Cohbar reportó gastos de investigación y desarrollo de $ 14.1 millones.

Año fiscal	Gastos de I + D
2022	$ 14.1 millones
2021	$ 16.3 millones

Inversiones de ensayos clínicos

Cohbar ha invertido significativamente en ensayos clínicos para sus terapias peptídicas derivadas de mitocondriales.

• Ensayos clínicos en curso para CHMB287 en obesidad y trastornos metabólicos
• Desarrollo preclínico de CHMB801 para el tratamiento del síndrome de dificultad respiratoria aguda

Mantenimiento de patentes e propiedad intelectual

Al 31 de diciembre de 2022, Cohbar mantuvo 26 patentes emitidas y 20 solicitudes de patentes pendientes a nivel mundial.

Tipo de patente	Número
Patentes emitidos	26
Aplicaciones de patentes pendientes	20

Salarios de personal científico

Cohbar reportó gastos totales de personal de $ 8.2 millones para el año fiscal 2022.

Costos operativos de laboratorio

Los gastos relacionados con el laboratorio y las instalaciones para 2022 totalizaron aproximadamente $ 3.5 millones, incluidos equipos, suministros y mantenimiento.

Categoría de gastos	Cantidad (2022)
Gastos operativos totales	$ 23.6 millones
Investigación y desarrollo	$ 14.1 millones
General y administrativo	$ 5.3 millones

Cohbar, Inc. (CWBR) - Modelo de negocio: flujos de ingresos

Acuerdos potenciales de licencia terapéutica

A partir del cuarto trimestre de 2023, Cohbar aún no ha generado ingresos a partir de acuerdos de licencia terapéutica. La Compañía continúa buscando posibles asociaciones para su plataforma de péptidos derivados de mitocondriales (MDP).

Subvenciones de investigación

Fuente de financiación	Monto de subvención	Año
Institutos Nacionales de Salud (NIH)	$1,258,000	2023
Ministerio de defensa	$750,000	2023

Financiación de la investigación colaborativa

Cohbar tiene esfuerzos de investigación colaborativos continuos con instituciones académicas y de investigación, aunque los detalles financieros específicos no se divulgan públicamente para todas las asociaciones.

Futuras asociaciones de desarrollo farmacéutico

• Posibles asociaciones en enfermedades metabólicas
• Investigación continua en terapéutica peptídica derivada de mitocondriales
• Discusiones exploratorias con compañías farmacéuticas

Pagos potenciales de hitos

A partir del informe financiero de 2023, Cohbar aún no ha recibido pagos significativos de hitos de colaboraciones estratégicas. Los posibles pagos de hitos de la compañía siguen siendo dependientes de futuras investigaciones y progreso del desarrollo.

Métrica financiera	Cantidad	Período
Gastos totales de investigación y desarrollo	$ 14.3 millones	2023
Equivalentes de efectivo y efectivo	$ 17.4 millones	P4 2023

CohBar, Inc. (CWBR) - Canvas Business Model: Value Propositions

You're looking at the core promise CohBar, Inc. (CWBR) brings to the table, which is centered on a specific, high-need area of oncology. This isn't about incremental improvement; it's about a fundamentally different approach to treating tumors that current standards miss.

Novel, personalized cancer vaccine for solid tumors

The value proposition here is the development of IFx-Hu2.0, described as a novel personalized cancer vaccine. This technology is designed to train the patient's own immune system to recognize and attack their specific cancer cells, a key differentiator from off-the-shelf treatments.

Potential treatment for checkpoint inhibitor-resistant cancers

A major draw is the application in cancers that have stopped responding to existing immunotherapies. The Phase 1b trial results, announced in partnership with Morphogenesis, Inc., specifically targeted advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) in patients who were checkpoint inhibitor resistant. This addresses a critical clinical failure point.

Overcoming tumor immune evasion mechanisms

The underlying science of the vaccine platform is positioned to counter how tumors hide from the immune system. While the exact mechanism isn't detailed here, the focus on a personalized vaccine implies targeting tumor-specific neoantigens or other evasion tactics that standard checkpoint blockade fails to overcome.

Addressing a significant unmet medical need in oncology

The market context shows a massive and growing need. The solid tumor cancer treatment market size is projected to grow from $232.2 billion in 2024 to $265.41 billion in 2025. Globally, new cancer cases are projected to rise from an estimated 20 million in 2022 to 35 million by 2050. In the U.S. alone, over 2 million new cancer diagnoses are expected in 2025. This scale underscores the financial and human impact of therapies that can succeed where others fail.

Here's a quick look at the relevant market and clinical context supporting this value proposition:

Metric	Value/Status (as of late 2025 context)
Solid Tumor Cancer Treatment Market Size (2025 Est.)	$265.41 billion
Solid Tumor Market CAGR (2024-2025)	14.3%
U.S. New Cancer Diagnoses (2025 Est.)	Over 2 million
CohBar, Inc. (CWBR) Latest Indication Trial Phase	Phase 1b (IFx-Hu2.0)
IFx-Hu2.0 Target Cancers	Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
IFx-Hu2.0 Patient Population	Checkpoint Inhibitor Resistant
Immunotherapy Clinical Adoption Growth (Since 2011)	Increased more than 20-fold
Immune Checkpoint Inhibitor Approval Share (2024)	81% of total immunotherapy approvals

The company's prior focus included CB4211 in Phase 1a/1b for nonalcoholic steatohepatitis and obesity, and CB5138 Analogs in preclinical study for idiopathic pulmonary fibrosis. Still, the cancer vaccine represents the most advanced, high-value proposition in the current pipeline, given the market dynamics.

You should note that as of early 2025, CohBar, Inc. (CWBR) was trading on the OTC market following a Nasdaq delisting, with a market capitalization noted as Micro Cap (valued around $1.19 million in January 2025 context). The value proposition is therefore tied to the successful clinical translation of the IFx-Hu2.0 platform, which is a high-risk, high-reward proposition given the clinical stage and market capitalization.

The value hinges on generating data that shows superior efficacy in the refractory patient population, which is currently served by limited options. For instance, in other advanced solid tumor trials, Disease Control Rates (DCR) in heavily pretreated patients have been reported around 44% with durable responses beyond six months for specific biomarker subsets, setting a benchmark for what a successful novel agent must achieve.

• Personalized approach aims to address tumor heterogeneity.
• Targets cancers refractory to existing checkpoint blockade.
• Leverages immune system reactivation beyond current targets.
• Addresses a market segment with high unmet clinical need.

Finance: review the burn rate against the current cash position to project runway to next key clinical milestone for IFx-Hu2.0 by end of Q1 2026.

CohBar, Inc. (CWBR) - Canvas Business Model: Customer Relationships

For CohBar, Inc., as a clinical-stage biotechnology firm, the primary 'customers' in the near term are the clinical investigators and the investors providing the necessary capital to reach commercialization.

High-touch, direct engagement with clinical investigators

Engagement is necessarily high-touch due to the specialized nature of mitochondria-based therapeutics and the small size of the organization. As of early 2025, CohBar, Inc. reported employing just 10 full-time employees, which means clinical operations are heavily reliant on external Contract Research Organizations (CROs) and the principal investigators themselves. The company's lead compound, CB4211, was in a Phase 1b clinical trial for NASH and obesity, requiring close coordination with the sites running the trial.

• Reliance on external CROs for site management.
• Direct communication channels established for trial execution.
• Focus on key opinion leaders in NASH and fibrosis research.

Investor relations to secure ongoing equity financing

Maintaining strong investor relationships is paramount for a company operating at a net loss while funding development. The trailing twelve months (TTM) net loss as of November 2025 was -$12.55 million, underscoring the need for continuous capital. The company's market capitalization stood at approximately $124.12 million as of April 22, 2025. Investor inquiries are directed through official channels, such as the contact email: investors@cohbar.com.

Metric	Value (as of late 2025 context)	Unit/Context
TTM Net Loss	-12.55	Million USD (as of November 2025)
Market Capitalization	124.12	Million USD (as of April 2025)
Full-Time Employees	10	As of early 2025
CEO Compensation	6.02	Million USD (November 2025)

Future direct sales force to oncologists and specialty clinics

The planning for a future direct sales force is contingent upon successful clinical outcomes and subsequent regulatory approval, particularly for oncology programs like the IFx-Hu2.0 vaccine candidate. Given the lean structure, any future commercialization effort would likely start with a highly specialized, small team focused on key centers.

• Commercialization strategy tied to IFx-Hu2.0 success.
• Team size projected to scale post-Phase 3 data readout.
• Focus on high-volume specialty clinics for initial launch.

CohBar, Inc. (CWBR) - Canvas Business Model: Channels

You're looking at the channels CohBar, Inc. (CWBR) uses to reach its key partners and stakeholders as of late 2025. Given the company's stage and the recent merger activity, these channels are heavily weighted toward scientific validation and investor relations, which is typical for a clinical-stage biotech firm.

Clinical trial sites and major cancer research centers

The primary channel for validating the core value proposition-mitochondria-based therapeutics-is through the execution of clinical trials. While specific site counts aren't public as of late 2025, the company's pipeline progress dictates channel activity. The lead compound, CB4211, was previously in a Phase 1a/1b trial for NASH and obesity, and preclinical programs like CB5138 Analogs target fibrotic diseases like idiopathic pulmonary fibrosis. The operational channel relies on established relationships with Clinical Research Organizations (CROs) to manage these sites.

The broader industry context shows that in 2025, the global CRO industry is projected to reach $90 billion by year-end, driven by decentralized trial innovations. This means CohBar, Inc.'s engagement with sites is likely digitized, utilizing integrated eClinical ecosystems where the use of digital tools by clinical trial sites rose to 81% in 2022, a trend that has certainly accelerated. The company's ability to secure high-quality sites is paramount, as sponsors avoid sites that repeatedly underperform.

Pipeline Program	Indication Focus	Last Known Development Stage (Pre-2025)
CB4211	NASH and Obesity	Phase 1b
CB5138 Analogs	Idiopathic Pulmonary Fibrosis (IPF)	Preclinical
IFx-Hu2.0 (via Morphogenesis merger)	Merkel Cell Carcinoma (MCC) and cSCC	Phase 1b Positive Results (as of June 2023)

Scientific publications and medical conferences

Scientific dissemination is a critical channel for building credibility and attracting future partners. This involves publishing data in peer-reviewed journals and presenting at key medical conferences. The company's Mito+ platform and peptide discoveries must be validated through this channel to support the development of drug candidates.

Historically, data from the CB4211 study were presented at the American Association for the Study of Liver Disease (AASLD) 2021 Liver Meeting®. The channel strategy is to use these scientific forums to communicate progress on their pipeline, which includes over 100 mitochondrial derived peptides and over 1,000 analogs discovered to date. The success of this channel directly influences the attractiveness of the licensing channel.

• Data presentation at major medical society meetings.
• Publication in high-impact, peer-reviewed journals.
• Communication of intellectual property coverage, including over 65 patent applications filed historically.
• Presentations to key opinion leaders in mitochondrial biology.

Investor presentations and SEC filings

For a publicly traded entity, regulatory filings and investor outreach are the formal channels for communicating financial health and strategic direction. As of early 2025, CohBar, Inc. was trading on the OTC market, having transitioned from NASDAQ. The stock price on January 06, 2025, was $0.41, with a reported Market Cap of $1.19M, classifying it as a Micro Cap. By February 7, 2025, the price had moved to $0.88.

The most recent definitive financial data available reflects a period before the full integration following the merger agreement with Morphogenesis, Inc. The channel for investor information relies on timely 10-K and 10-Q filings, which provide the official record of cash reserves and operating expenses. The shift in listing venue itself is a key communication point to the investment community.

Metric	Value/Status	Date Reference
Stock Price (Low Reference)	$0.41 USD	January 06, 2025
Market Capitalization	$1.19M USD	January 06, 2025
Exchange Listing	OTC	As of January 2025
Historical NME Revenue Driver	70 percent from external sourcing (Industry Trend)	Since 2018

Future pharmaceutical licensing partners

This is arguably the most crucial external channel for a clinical-stage company like CohBar, Inc. The strategy explicitly involves advancing drug candidates through strategic partnerships with larger biopharmaceutical companies. The merger with Morphogenesis, Inc. itself represents a major strategic alignment, but the pipeline development still requires external validation and commercialization reach.

The industry trend in 2025 reinforces this channel's importance: large pharma companies are becoming more selective regarding early-stage R&D, making them increasingly reliant on external innovation and clinical-stage dealmaking to fill their pipelines. CohBar, Inc.'s intellectual property portfolio, covering over 100 natural peptides and analogs, serves as the primary asset being channeled to these potential partners. The goal is to secure deals that capture maximum value, whether through internal development or partnership.

• Targeting larger biopharmaceutical companies for in-licensing.
• Leveraging strong IP coverage to enhance deal attractiveness.
• Focusing on clinical-stage assets for potential partnerships.
• Utilizing scientific conference presence to network with potential dealmakers.

Finance: draft 13-week cash view by Friday.

CohBar, Inc. (CWBR) - Canvas Business Model: Customer Segments

You're looking at the core groups that CohBar, Inc. (CWBR) needs to engage to move its pipeline forward, especially given its clinical-stage status and recent corporate activity. Honestly, for a company like this, the customer segments aren't just end-users; they are critical partners and funders.

Patients with advanced, solid tumors resistant to standard therapies

This segment represents the ultimate beneficiaries for the preclinical cancer assets, such as the MBT3 Analogs for cancer immunotherapy and MBT5 Analogs for CXCR4-related cancer. The sheer scale of the patient population needing novel options is substantial, grounding the commercial potential. In the United States in 2025, there are approximately 2,041,910 new cancer diagnoses projected to occur. Solid tumors represent around 85% of these cases. For context on the need for advanced therapies, the global solid tumor therapeutics market size stood at USD 207.29 billion in 2025. The U.S. solid tumor cancer treatment market size was evaluated at USD 1.32 billion in 2024.

The need for novel approaches is underscored by the fact that for certain cancers, like chronic myeloid leukemia, drug resistance occurs in 5% to 10% of patients. The patient pool for CohBar, Inc. is defined by the failure of existing lines of therapy, which is a significant subset of the total diagnosed population.

Oncologists and specialized cancer treatment centers

These are the clinical gatekeepers who will ultimately test and prescribe any successful therapeutic. Their focus is on centers treating complex, resistant cases. As of 2025, there are approximately 25,419 oncologists actively practicing in the United States. Within this group, the number of physicians tracked specializing in Hematology/oncology is 11,937. The demand for these specialists is high, with projections indicating a total shortfall of 2,258 full-time equivalent clinical care FTEs across the U.S. by 2025.

• The majority of oncologists, about 67.5%, work exclusively in urban settings.
• The density of medical and hematology oncologists relative to the aging population is decreasing.
• The total number of new cancer cases in the U.S. in 2025 is estimated at 2,041,910.

Large pharmaceutical companies seeking late-stage oncology assets

These entities are the primary potential acquirers or partners for CohBar, Inc.'s pipeline assets, especially if they advance past preclinical stages, like the CB4211 (NASH/Obesity) or CB5138 Analogs (IPF). Big Pharma is actively seeking bolt-on deals, particularly in oncology. For instance, one major oncology deal in June 2025 between Bristol Myers Squibb and BioNTech had a total value of $11 billion, including $1.5 billion upfront. Another illustrative deal in the first half of 2025 involved a value of approximately $14.6 billion. Furthermore, approximately 85% of China out-licensing deals are focused on oncology, showing a global appetite for external oncology innovation.

The industry holds significant capital, with biopharma companies holding US$1.3 trillion in dealmaking Firepower as of early 2025, though the focus has shifted to smaller, smarter deals.

Institutional and retail investors funding the development stage

This segment provides the necessary capital to fund the multi-year, high-cost clinical development process. For CohBar, Inc., as of November 30, 2025, the stock price was $0.41, and the market capitalization as of January 16, 2025, was $1.19M. The company, which employs around 9 to 10 full-time employees, has generated over 1,000 analogs from its discovery platform. The company's stock trades on the OTCMKTS exchange following a delisting notice in November 2023.

Financial Metric	Value/Amount	Date Context
Stock Price	$0.41	November 30, 2025
Market Capitalization	$1.19M	January 16, 2025
Full Time Employees	9	2025 Data
Total Mitochondrial Derived Peptide Analogs Generated	Over 1,000	Preclinical Data
Total Oncology Deals Value (Largest Example 1H 2025)	$11 billion	June 2025

The company's ability to attract funding is directly tied to the progression of its lead candidates, CB4211 and CB5138 Analogs, through clinical milestones.

CohBar, Inc. (CWBR) - Canvas Business Model: Cost Structure

You're looking at the core expenses CohBar, Inc. (CWBR) faces to keep its pipeline moving, which is typical for a clinical-stage biotech. The cost structure is heavily weighted toward discovery and development, meaning cash burn is the primary financial reality until a partnership or commercial success hits.

High Research and Development (R&D) expenses form the largest component of the operating cost structure. This covers everything from preclinical work to managing ongoing clinical trials. For instance, R&D spending for the first quarter of 2024 was reported at around $1.8 million.

Clinical trial costs are embedded within the R&D spend and are highly variable based on the phase and complexity of the drug candidate, such as CB5138-3 targeting Idiopathic Pulmonary Fibrosis (IPF). While the Q1 2024 R&D was $1.8 million, historical data shows quarterly R&D costs fluctuating, such as $1.5 million in Q1 2022 and $2.2 million in Q4 2022 [cite: 5 from previous search].

General and administrative (G&A) overhead covers the necessary operational expenses outside of the lab and trials. This includes executive salaries, rent, and general corporate functions. The latest available quarterly G&A figure we have is from mid-2023, where it stood at $4.3 million for the quarter ended June 30, 2023 [cite: 2 from previous search].

Intellectual property maintenance and legal fees are a distinct, recurring cost necessary to defend and maintain the company's competitive moat. These costs are often bundled into G&A, but specific maintenance fees are required to keep patent families active. For example, aggregate annual maintenance fees paid to licensors for two specific agreements totaled $87,500 in 2022 [cite: 1 from previous search].

Here's a quick look at how some of these key operating expenses have tracked quarterly, showing the variability in R&D versus the more stable G&A base:

Period	R&D Expense (Approximate)	G&A Expense (Approximate)
Q1 2024	$1.8 million	Data not explicitly available for this quarter
Q2 2023	$0.17862 million	$4.3 million [cite: 2 from previous search]
Q1 2023	$1.0 million	$1.3 million [cite: 2 from previous search]
Q4 2022	$2.2 million	$1.7 million [cite: 2 from previous search]

The primary cost drivers CohBar, Inc. (CWBR) manages are:

• Funding IND-enabling studies and formulation work.
• Managing patent prosecution and international filings.
• Covering fixed costs like executive compensation and facilities.
• Paying annual patent maintenance fees, such as the $87,500 paid across key licenses in 2022 [cite: 1 from previous search].

What this estimate hides is the potential for large, one-time legal expenses related to litigation or significant IP defense, which would spike the G&A line item.

CohBar, Inc. (CWBR) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of CohBar, Inc. (CWBR) as of late 2025, and honestly, it's what you'd expect for a company deep in clinical development. The model isn't built on selling anything yet; it's built on capital preservation and hitting milestones.

Currently $0 from core product sales (pre-commercial stage)

As of the latest fiscal year fundamentals, CohBar, Inc.'s reported revenue from core operations is $0. This is the reality for a pre-commercial biotech focused on advancing its pipeline, specifically the lead asset, IFx-Hu2.0. Since IFx-Hu2.0 is in a Phase 3 accelerated approval trial as of mid-2025, product sales revenue is not yet a factor in the current model.

Future milestone payments from potential licensing agreements

The near-term potential for non-dilutive cash flow hinges on securing a licensing agreement for IFx-Hu2.0 or other pipeline assets. These deals typically structure payments around specific achievements:

• Non-refundable upfront payments upon signing.
• Development milestone payments tied to clinical trial completions.
• Regulatory milestone payments upon FDA approval.

Future royalties on net sales of IFx-Hu2.0

Once IFx-Hu2.0 potentially gains market approval-it's being evaluated in a Phase 3 trial for advanced or metastatic Merkel cell carcinoma (MCC) as of June 2025-the long-term revenue stream will shift to royalties. This is the ultimate goal of the development strategy.

Here's a quick look at the financial context supporting the current operations:

Financial Metric	Amount (TTM)	Implication
Revenue from Core Operations	$0	No product sales; entirely reliant on financing.
Net Income (Profit/Loss)	-$12.55 million	Represents the cash burn rate that financing must cover.
Market Capitalization (Early 2025 Estimate)	$1.19 million	Highlights the high reliance on external capital given the low valuation base.

Equity financing and capital raises to cover the TTM net loss of -$12.55 million

Since product revenue is zero, the current financial lifeline for CohBar, Inc. is its ability to raise capital to fund its operations and clinical trials. The Trailing Twelve Months (TTM) net loss of -$12.55 million must be covered by these financing activities to maintain the runway. This is the primary, current source of operational funding.

The company's cash generation strategy, therefore, looks like this:

• Primary Funding Source: Issuance of common stock and warrants in public offerings.
• Secondary Potential: Upfront payments from any pre-commercial licensing deals.
• Key Risk: Dilution of existing shareholder equity with each capital raise.

Finance: draft 13-week cash view by Friday.